Liquid Biopsy Market to Reach a Valuation of US$ 2.89 Bn by 2026

Future Market Insights presents an in-depth analysis as well as a revised forecast for the global liquid biopsy market in a new report titled ‘Liquid Biopsy Market: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2027).’ The revised forecasts indicate that the global liquid biopsy market is estimated to be worth US$ 456.0 Mn by 2017 end, and is expected to expand at a CAGR of 20.6% over the forecast period of 2017–2027 to reach a market valuation of US$ 3,130.7 Mn by the end of the forecast period in 2027. The revision in the market size and forecasts have been carried out taking into account the impact of various macroeconomic indicators and other industry based demand driving factors, as well as the recent developments of key market participants. The global liquid biopsy market is projected to expand at a healthy CAGR of 20.6% in terms of value during the forecast period, revised from the previous CAGR of 21.7%.

Global Liquid Biopsy Market: Segmental Forecast

The global liquid biopsy market is segmented on the basis of biomarker type, sample type, disease indication, end user and region. On the basis of biomarker type, the market has been segmented into CTC (Circulating Tumor Cells), ctNA (Circulating Tumor Nucliec Acids), Exosomes. CTC (Circulating Tumor Cells) is the largest biomarker segment in the liquid biopsy market, which is estimated to reach a market valuation of US$ 1,542.0 Mn by 2027, expanding at CAGR of 18.2% over the forecast period 2017–2027.

Based on sample type, the liquid biopsy market is segmented into blood, urine and other. Blood sample segment is expected to dominate the global liquid biopsy market, registering a CAGR of 20.5% in terms of value during the forecast period.

Report Overview @ https://www.futuremarketinsights.com/reports/liquid-biopsy-market

On the basis of disease indication the global liquid biopsy market is segmented into lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, colorectal cancer, leukemia and others. Lung cancer segment dominated the global liquid biopsy market in revenue terms in 2016 and is projected to continue to do so throughout the forecast period. Lung cancer segment is projected to be the most attractive segment with attractiveness index of 2.9 during the forecast period.

Based on end user, the global liquid biopsy market is segmented into hospitals, cancer institutes, academic institutes and diagnostic centres. Cancer Institutes end user segment dominated the global liquid biopsy market in revenue terms in 2016 and is projected to continue to do so throughout the forecast period. Cancer institutes segment is projected to be the most attractive segment with attractiveness index of 1.6 during the forecast period.

On the basis of region, the global liquid biopsy market has been segmented into North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan and MEA. North America dominated the global liquid biopsy market with 51% value share in 2016, and is expected to continue to dominate the global market throughout the forecast period. Availability of beneficial reimbursement schemes for cancer diagnosis and treatment is expected to fuel revenue growth of this regional market. Increasing government funding on cancer research is also expected to boost revenue growth of the liquid biopsy market in North America. Western Europe is expected to be the second most lucrative market, with an attractiveness index of 1.8 during the forecast period. Western Europe is closely followed by APEJ with a market attractiveness index of 1.5.

Request to Sample Report - https://www.futuremarketinsights.com/reports/sample/rep-gb-5593

Summary of Table of Content
1. Executive Summary
2. Market Introduction
3. Liquid Biopsy Market View Point Analysis
4. North America Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027
5. Latin America Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027
6. Western Europe Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027
7. Eastern Europe Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027
8. Asia Pacific excluding Japan Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027
9. Japan Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027
10. Middle East & Africa Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027
11. Competition Landscape
13. Global Pain Therapeutic Solutions Market Analysis 2012–2016 and Forecast 2017–2027, By Biomarker Type
14. Global Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027, By Sample Type
15. Global Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027, By Disease Indication
16. Global Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027, By End User
17. Global Liquid Biopsy Market Analysis 2012–2016 and Forecast 2017–2027
18. Assumptions and Acronyms Used
19. Research Methodology

Request to Browse Full Table of Content, figure and Tables @ https://www.futuremarketinsights.com/reports/liquid-biopsy-market-112017/toc

ABOUT US:
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.

CONTACT:
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Website :www.futuremarketinsights.com

This release was published on openPR.